Clinical trials: Adult Gliosarcoma
Brain and Central Nervous System Tumors
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
RATIONALE: EMD 121974 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of EMD 121974 in treating patients who have progressive or recurrent malignant glioma.
- Trial name
- NCT00006093
- Testing
- cilengitide
- Where
- 10 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Brain and Central Nervous System Tumors
O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy
RATIONALE: Drugs used in chemotherapy, such as O(6)-benzylguanine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00436436
- Testing
- O6-benzylguanine, temozolomide
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
This phase I trial studies the side effects and determines the best dose of genetically modified neural stem cells and flucytosine when given together with leucovorin for treating patients with recurrent high-grade gliomas.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT02015819
- Testing
- E. coli CD-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Brain and Central Nervous System Tumors
Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for patients with glioma.
- Trial name
- NCT00003916
- Testing
- radiation therapy, stereotactic radiosurgery
- Where
- 8 sites in Australia, France and 5 more
- Volunteers
- 25 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent Adult Brain Tumor
Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy, such as Gliadel wafer and O6-benzylguanine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00362921
- Testing
- Gliadel wafers in combination with O6-benzylguanine
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Duke University
Acoustic Schwannoma, Adult Anaplastic (Malignant) Meningioma
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
This phase I trial studies the side effects and best dose of gamma-secretase/Notch signalling pathway inhibitor RO4929097 (RO4929097) when given together with temozolomide and radiation therapy in treating patients with newly…
- Conditions
- Acoustic Schwannoma, Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
- Trial name
- NCT01119599
- Testing
- 3-Dimensional Conformal Radiation Therapy, Gamma-Secretase Inhibitor RO4929097, Intensity-Modulated Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Boron Neutron Capture Therapy Following Surgery in Treating Patients With Glioblastoma Multiforme Removed During Surgery
RATIONALE: Boron neutron capture therapy may selectively kill tumor cells without harming normal tissue. PURPOSE: This phase I trial is studying the side effects and best dose of boron neutron capture therapy following surgery in…
- Trial name
- NCT00004015
- Testing
- sodium borocaptate, adjuvant therapy
- Where
- 8 sites in Austria, Canada and 4 more
- Volunteers
- 36 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain and Central Nervous System Tumors
Gene Therapy in Treating Patients With Recurrent or Progressive Brain Tumors
RATIONALE: Inserting the gene for p53 into a person's brain cells may improve the body's ability to fight cancer. PURPOSE: Phase I trial to study the effectiveness of p53 gene therapy with SCH-58500 in treating patients who have…
- Trial name
- NCT00004080
- Testing
- recombinant adenovirus-p53 SCH-58500, conventional surgery
- Sponsor
- National Cancer Institute (NCI)
Brain Cancer
Phase I/II Cabazitaxel for Recurrent Malignant Glioma
The goal of Part 1 of this clinical research study is to find the highest tolerable dose of cabazitaxel that can be given to patients with glioblastoma.
- Trial name
- NCT01740570
- Testing
- Cabazitaxel
- Sponsor
- M.D. Anderson Cancer Center
Adult Glioblastoma Multiforme
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Monoclonal antibodies, such as ramucirumab and anti-PDGFR alpha monoclonal antibody IMC-3G3 (Olaratumab), can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00895180
- Testing
- olaratumab, ramucirumab
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Malignant Gliomas
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
The goal of this clinical research study is to find the highest tolerable dose of lenalidomide combined with Camptosar (irinotecan) as well as to see if this drug combination can help control malignant gliomas.
- Trial name
- NCT00671801
- Testing
- Irinotecan, Lenalidomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
This phase I trial studies the side effects and best dose of tipifarnib when given together with radiation therapy and temozolomide in treating patients with newly diagnosed glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT02227901
- Testing
- Tipifarnib, External Beam Radiation Therapy, Temozolomide
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
RATIONALE: Erlotinib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have recurrent or…
- Trial name
- NCT00054496
- Testing
- erlotinib hydrochloride
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- The Cleveland Clinic
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT00030498
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Computer systems that allow doctors to create a 3-dimensional picture of the tumor in order to plan treatment may result in more effective radiation…
- Trial name
- NCT00003417
- Testing
- carmustine, radiation therapy
- Where
- 237 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- Radiation Therapy Oncology Group
Brain and Central Nervous System Tumors
Radiation Therapy in Treating Patients With Progressive or Recurrent Malignant Brain Tumors
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Trial name
- NCT00003574
- Testing
- surgical procedure, brachytherapy, intraoperative radiation therapy
- Where
- 9 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Glioblastoma, Glioblastoma (GBM)
A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma
The purpose of this study is to determine how safe and how well-tolerated the experimental study drug, C134 is when administered twice into the brain where the tumor is located. This is a Phase IB 2 dosing study.
- Conditions
- Glioblastoma, Glioblastoma (GBM), Astrocytoma, Astrocytoma, Grade III
- Trial name
- NCT06614855
- Testing
- C134
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- James Markert, MD
Brain and Central Nervous System Tumors
Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of cancer cells and slow the growth of the tumor.
- Trial name
- NCT00027625
- Testing
- gefitinib, temozolomide
- Where
- 11 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brain and Central Nervous System Tumors
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Erlotinib and sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of erlotinib when given…
- Trial name
- NCT00509431
- Testing
- Erlotinib + Sirolimus
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in higher doses over a shorter period of time may kill more tumor cells and have fewer side effects.
- Trial name
- NCT00820963
- Testing
- temozolomide, hypofractionated radiation therapy, radiation therapy
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Centre Leon Berard